MedComm

SJR Rank #743H-index: 57SJR: 2.930Best quartile: Q1Open AccessAPC: US$3,500Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

John Wiley and Sons Inc

Country

United States

Type

journal

SJR by Edition

Only one SJR edition is available for this journal so far.

Subject Categories

  • Biochemistry (medical)Q1
  • Cell BiologyQ1
  • Drug DiscoveryQ1
  • GeneticsQ1
  • Genetics (clinical)Q1
  • Immunology and AllergyQ1
  • OncologyQ1

Areas: Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Cancer Immunotherapy and BiomarkersImmune cells in cancerRNA modifications and cancerSARS-CoV-2 and COVID-19 ResearchEpigenetics and DNA MethylationFerroptosis and cancer prognosisImmune Cell Function and InteractionCancer-related molecular mechanisms researchAutophagy in Disease and TherapyCancer, Hypoxia, and Metabolism

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0200400600800

Documents per Year

Only one SJR edition is available for this journal so far.

Detailed Information

ISSN

2688-2663

SJR Best Quartile

Q1

Region

Northern America

Citations per Document (2 years)

11.73

References per Document

146.57

Coverage

2020-2026

Scope

No scope description available yet.

Metrics from SCImago Journal Rank 2025. View on SCImago